✦ LIBER ✦

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)

✍ Scribed by Jose Antonio Marin-Neto; Anis Rassi Jr; Carlos A. Morillo; Alvaro Avezum; Stuart J. Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf

Book ID: 116191419
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 142 KB
Volume: 156
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2008.04.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design for TIME: A phase I

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction

✍ Jay H. Traverse; Timothy D. Henry; Douglas E. Vaughn; Stephen G. Ellis; Carl J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 158 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Design and Rationale of the PROTECT Stud

Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

✍ Beth Davison Weatherley; Gad Cotter; Howard C. Dittrich; Paul DeLucca; George A. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 217 KB

A multicentre, randomized, double-blind

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

✍ Olivier F. Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 803 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—study design and rationale

✍ Rajendra H. Mehta; John H. Alexander; Robert Emery; Stephen J. Ellis; Vic Hassel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Rationale and design of the dual antipla

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions

✍ Laura Mauri; Dean J. Kereiakes; Sharon-Lise T. Normand; Stephen D. Wiviott; Davi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 307 KB